Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer and other types of solid tumors. According to the provided sources, there is no specific recommended duration of lurbinectedin treatment, as it depends on various factors such as the patient's response to the drug and the severity of the cancer.

The drug patent watch [1] provides information on the patent status of the drug and its approved indications but does not mention the recommended duration of treatment. The PMC article [2] reports the results of a phase II clinical trial of lurbinectedin in patients with relapsed small cell lung cancer. The study found that the drug was well-tolerated and had a response rate of 35.7%. However, the article does not provide information on the recommended duration of treatment.

The Lancet Oncology article [3] discusses the results of a phase III clinical trial of lurbinectedin in patients with small cell lung cancer. The study found that the drug improved progression-free survival compared to standard chemotherapy. However, the article does not mention the recommended duration of treatment.

In summary, the provided sources do not provide a specific recommended duration of lurbinectedin treatment. The duration of treatment is likely to vary depending on the individual patient's response to the drug and the stage and severity of their cancer. Patients should consult with their healthcare provider to determine the appropriate duration of treatment for their specific case.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext